The nation of Zimbabwe has turned down a substantial US health deal worth 367 million US dollars (272 million pounds) spanning five years due to the United States' demand for sensitive biological samples.
This move became public following a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson later clarified that the United States was seeking health data for scientific study and profit while was unwilling to share the benefits from any future treatments.
"We must now begin the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued talks to find a agreement suitable to both sides so the country's critical HIV programme can continue.
Broader Background
This rejection comes after a similar case in Kenya, where a high court suspended a related health funding agreement following legal challenges were filed about the safety of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost openness and responsibility.
According to reports, 16 nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our nation would provide the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our population if a future disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures previously established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This system is intended to ensure that when a nation contributes its information, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We encourage ongoing dialogue with our US partners on how subsequent co-operation might be structured in a way that respects the independence and interests of both nations."
Health Experts Response
Medical experts said it acknowledged the official position, but suggested that negotiations must proceed given that a large portion of the country's HIV programmes relied on external financing.
"Where technical issues exist, including those relating to data governance or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
This impasse underscores the ongoing challenges between receiving vital foreign assistance and safeguarding local interests in an ever more data-driven world.